Key Takeaway
Retatrutide is expected to receive FDA approval in late 2026 or 2027, pending the completion of Phase 3 clinical trials by Eli Lilly. Learn about the current timeline and what it means for patients.
Retatrutide is projected to receive FDA approval in late 2026 or 2027. Eli Lilly is currently conducting Phase 3 clinical trials, and submission of a New Drug Application (NDA) will follow once those trials conclude with favorable results. No exact approval date has been confirmed by the FDA or Eli Lilly.
Detailed Explanation
Retatrutide is a triple-hormone receptor agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. This triple-agonist mechanism sets it apart from existing GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which target only one or two receptors.
The Phase 2 clinical trial results, published in the New England Journal of Medicine in 2023, showed that participants lost up to 24.2% of their body weight over 48 weeks[1] at the highest dose. These results were considered notable and prompted Eli Lilly to advance the drug into Phase 3 trials.
Phase 3 trials are large-scale studies that evaluate safety and efficacy across diverse patient populations. These trials typically take 18 to 36 months to complete. Eli Lilly initiated its Phase 3 program for retatrutide in late 2023, with multiple trials running simultaneously across obesity and type 2 diabetes indications.
Once Phase 3 data is collected and analyzed, Eli Lilly will submit an NDA to the FDA. The FDA review process typically takes 10 to 12 months from the date of submission. Priority review designation, if granted, could shorten that window to approximately 6 months.
Based on this timeline, the earliest realistic FDA approval would fall in late 2026. A 2027 approval is considered more likely by most industry analysts, depending on trial enrollment speed, data readout timing, and the FDA review process.
What to Consider
- Approval isn't guaranteed. Phase 3 trials may reveal safety concerns or efficacy results that differ from Phase 2 data, which could delay or prevent approval.
- Separate approvals may be needed. Eli Lilly may seek approval for obesity and type 2 diabetes as distinct indications, potentially at different times.
- Supply constraints are possible. Even after approval, manufacturing scale-up could limit initial availability, similar to the shortages seen with Ozempic, Mounjaro, and Zepbound.
- Compounding access may change. the regulatory space for compounded GLP-1 medications continues to evolve and could be affected by retatrutide's approval status.
- Physician-supervised alternatives exist now. Patients interested in GLP-1 or peptide therapy don't need to wait for retatrutide. Telehealth providers like FormBlends offer access to currently available, physician-supervised treatments.
Related Questions
Frequently Asked Questions
How does retatrutide differ from semaglutide and tirzepatide?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, compared to semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP). This triple mechanism showed higher average weight loss in early clinical trials.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
What weight loss results has retatrutide shown in trials?
Phase 2 trial data published in the New England Journal of Medicine showed participants lost up to 24.2% of body weight at the highest dose over 48 weeks[1]. Phase 3 trials are evaluating these results in larger, more diverse patient populations.
When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials. If trial results are positive, Eli Lilly could submit for FDA approval as early as 2025-2026, with potential commercial availability following approval. Timelines are subject to change based on regulatory review.
Medical References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed | ClinicalTrials.gov | DOI]
Take the Next Step
You don't have to wait for retatrutide to start a physician-supervised weight loss program. FormBlends connects you with licensed providers who can evaluate your health profile and prescribe GLP-1 or peptide therapy that's available today. Start your free consultation to learn which treatment option fits your goals.